References
- Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y. oxLDL/β2-GPI complexes: New aspects in atherosclerosis. Lupus 2005; 14(9)736–741
- Shoenfeld Y, Gerli R, Doria A, Matsuura E, Matucci Cerinic M, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112(21)3337–3347
- Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with SLE. Ann Rheum Dis 2003; 62(11)1071–1077
- Zampieri S, Iaccarino L, Ghirardello A, Taricone E, Arienti S, Sarzi-Puttini P, et al. SLE, atherosclerosis, and AAb. Ann NY Acad Sci 2005; 1051: 351–361
- Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, et al. Fifth International Congress on Autoimmunity. Autoimmun Rev 2006; 12: 19–20, Sorrento, Italy, November 29–December 3
- Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, et al. Lipid peroxidation is enhanced in patients with SLE and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52(1)192–200
- Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, et al. Oxidative stress in SLE: Relationship to disease activity and symptoms. Lupus 2007; 16(3)195–200
- Njoku CJ, Patrick KS, Ruiz P, Jr, Oates JC. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med 2005; 53(7)347–352
- Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in SLE: Prevalence and association with APL. J Rheumatol 2003; 30: 985–992
- Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, et al. AAb and neuropsychiatrc events at the time of SLE diagnosis. Arthritis Rheum 2008; 58(3)843–853